文献速递类风湿关节炎其他结缔组织病

类风湿关节炎临床前肺实质疾病的筛查

Screening for preclinical parenchymal lung disease in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

研究对无间质性肺病(ILD)或慢性阻塞性肺疾病诊断的106例类风湿关节炎(RA)患者行前瞻性全面评估,高分辨CT(HRCT)评分临床前肺气肿和临床前ILD。78例(74%)存在肺部影像和/或功能异常,45%有临床前肺实质疾病,以临床前肺气肿(36%)最常见,临床前ILD为15%;临床、实验室和功能评估未能充分识别临床前肺实质异常,HRCT可能是目前最有效的筛查方法。

要点

  • 106例RA患者中45%存在临床前肺实质疾病,临床前肺气肿最常见(36%)。
  • 临床前肺气肿与年龄较大、抗环瓜氨酸肽抗体滴度较高及弥散功能异常相关。
  • 47%的临床前肺气肿发生于从不吸烟者,以全小叶型为主。

核心结论

  • RA中存在高比例的未诊断临床前肺实质疾病,主要由孤立性肺气肿驱动,提示其可能是RA常见且此前未被识别的肺部表现,即使在从不吸烟者中也是如此。
  • 由于临床、实验室和功能评估未能充分识别临床前肺实质异常,HRCT可能是目前可用于RA患者的最有效筛查方式。

研究设计与样本

  • 前瞻性研究,纳入无ILD或慢性阻塞性肺疾病诊断的RA患者106例,接受全面临床、实验室、功能和影像学评估。
  • HRCT扫描对临床前肺气肿和临床前ILD进行评分,并评估其他异常。

主要发现

  • 106例受试者中78例(74%)存在肺部影像和/或功能异常,45%有临床前肺实质疾病。
  • 有临床前肺实质疾病的个体年龄较大、弥散能力较低,吸烟史与无疾病者相似。
  • 临床前肺气肿(36%)是最常检出的异常,与年龄较大、较高的抗环瓜氨酸肽抗体滴度和弥散功能异常相关。
  • 相当比例的临床前肺气肿发生于从不吸烟者(47%),以全小叶型为主。
  • 临床前ILD(15%)与临床、实验室或功能指标均无关联。

临床怎么用

  • 作者认为HRCT可能是目前可用于RA患者临床前肺实质异常的最有效筛查方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pulmonary disease is a common extraarticular manifestation of RA associated with increased morbidity and mortality. No current strategies exist for screening this at-risk population for parenchymal lung disease, including emphysema and interstitial lung disease (ILD). METHODS: RA patients without a diagnosis of ILD or chronic obstructive pulmonary disease underwent prospective and comprehensive clinical, laboratory, functional and radiological evaluations. High resolution CT (HRCT) scans were scored for preclinical emphysema and preclinical ILD and evaluated for other abnormalities. RESULTS: Pulmonary imaging and/or functional abnormalities were identified in 78 (74%) of 106 subjects; 45% had preclinical parenchymal lung disease. These individuals were older with lower diffusion capacity but had similar smoking histories compared with no disease. Preclinical emphysema (36%), the most commonly detected abnormality, was associated with older age, higher anti-cyclic citrullinated peptide antibody titres and diffusion abnormalities. A significant proportion of preclinical emphysema occurred among never smokers (47%) with a predominantly panlobular pattern. Preclinical ILD (15%) was not associated with clinical, laboratory or functional measures. CONCLUSION: We identified a high prevalence of undiagnosed preclinical parenchymal lung disease in RA driven primarily by isolated emphysema, suggesting that it may be a prevalent and previously unrecognized pulmonary manifestation of RA, even among never smokers. As clinical, laboratory and functional evaluations did not adequately identify preclinical parenchymal abnormalities, HRCT may be the most effective screening modality currently available for patients with RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Esposito AJ, Sparks JA, Gill RR, et al. Screening for preclinical parenchymal lung disease in rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34875040. doi:10.1093/rheumatology/keab891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。